{"id":"NCT00343889","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine","officialTitle":"Immunogenicity Study of a DTaP-Hep B-PRP-T Combined Vaccine Compared to Tritanrix-HepB/Hib™, Both Given Concomitantly With the Oral Polio Vaccine at 6, 10, and 14 Weeks of Age in Healthy Infants in the Philippines","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08","primaryCompletion":"2007-11","completion":"2008-04","firstPosted":"2006-06-23","resultsPosted":"2013-12-10","lastUpdate":"2013-12-10"},"enrollment":379,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Diphtheria","Tetanus","Pertussis","Hepatitis B","Haemophilus Infections"],"interventions":[{"type":"BIOLOGICAL","name":"DTaP-HB-PRP~T vaccine + OPV","otherNames":[]},{"type":"BIOLOGICAL","name":"Tritanrix-HepB/Hib™ + OPV vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Oral Polio Vaccine","otherNames":[]}],"arms":[{"label":"Group 1: DTaP-Hep B-PRP-T + Oral Polio Vaccine (OPV) vaccine","type":"EXPERIMENTAL"},{"label":"Group 2: Tritanrix-HepB/Hib™ + OPV vaccine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to support the registration of the pentavalent DTaP-HB-PRP\\~T vaccine in countries that follow the World Health Organization-Expanded Program of Immunization (WHO-EPI) schedule.\n\nThe primary objective is:\n\n* To demonstrate that the pentavalent DTaP-HB-PRP\\~T combined vaccine does not induce a lower immune response than Tritanrix-HepB/Hib™ in terms of the seroprotection rate to hepatitis B (HB) one month after a 3-dose primary series at 6, 10, and 14 weeks of age.\n\nThe secondary objectives are:\n\n* To describe in each group the immunogenicity parameters one month after the 3-dose primary series at 6, 10, and 14 weeks of age; and\n* To evaluate the overall safety in terms of any adverse events in the first 28 days after each injection and any serious adverse events during the entire trial.","primaryOutcome":{"measure":"Number of Participants With Seroprotection to Hepatitis H Antigen After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) or Tritanrix-Hep B/Hib™ Concomitantly With OPV","timeFrame":"1 month post third vaccination","effectByArm":[{"arm":"Group 1: DTaP-Hep B-PRP~T + OPV","deltaMin":146,"sd":null},{"arm":"Group 2: Tritanrix-Hep B/ Hib™ + OPV","deltaMin":167,"sd":null}],"pValues":[]},"eligibility":{"minAge":"42 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":2,"countries":["Philippines"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":190},"commonTop":["Injection site pain","Injection site erythemia","Irritability","Pyrexia","Upper respiratory tract infection"]}}